C4 Therapeutics (CCCC) Competitors $3.95 +0.10 (+2.60%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CCCC vs. CALT, SPRY, SNDX, ANIP, RCKT, BCYC, AVDL, COLL, SEPN, and BCAXShould you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Calliditas Therapeutics AB (publ) (CALT), ARS Pharmaceuticals (SPRY), Syndax Pharmaceuticals (SNDX), ANI Pharmaceuticals (ANIP), Rocket Pharmaceuticals (RCKT), Bicycle Therapeutics (BCYC), Avadel Pharmaceuticals (AVDL), Collegium Pharmaceutical (COLL), Septerna (SEPN), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry. C4 Therapeutics vs. Calliditas Therapeutics AB (publ) ARS Pharmaceuticals Syndax Pharmaceuticals ANI Pharmaceuticals Rocket Pharmaceuticals Bicycle Therapeutics Avadel Pharmaceuticals Collegium Pharmaceutical Septerna Bicara Therapeutics C4 Therapeutics (NASDAQ:CCCC) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment. Which has more risk and volatility, CCCC or CALT? C4 Therapeutics has a beta of 2.92, indicating that its stock price is 192% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Is CCCC or CALT more profitable? Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to C4 Therapeutics' net margin of -313.35%. C4 Therapeutics' return on equity of -42.45% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-313.35% -42.45% -27.55% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Does the MarketBeat Community favor CCCC or CALT? C4 Therapeutics and Calliditas Therapeutics AB (publ) both received 27 outperform votes by MarketBeat users. However, 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote while only 39.13% of users gave C4 Therapeutics an outperform vote. CompanyUnderperformOutperformC4 TherapeuticsOutperform Votes2739.13% Underperform Votes4260.87% Calliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Which has preferable earnings & valuation, CCCC or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than C4 Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$33.67M8.28-$132.49M-$1.70-2.32Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Does the media refer more to CCCC or CALT? In the previous week, C4 Therapeutics had 6 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 6 mentions for C4 Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). C4 Therapeutics' average media sentiment score of 1.05 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Overall Sentiment C4 Therapeutics Positive Calliditas Therapeutics AB (publ) Neutral Do analysts prefer CCCC or CALT? C4 Therapeutics presently has a consensus target price of $10.67, suggesting a potential upside of 170.04%. Calliditas Therapeutics AB (publ) has a consensus target price of $39.25, suggesting a potential downside of 1.88%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe C4 Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders hold more shares of CCCC or CALT? 78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 8.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryC4 Therapeutics beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CCCC vs. The Competition Export to ExcelMetricC4 TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$278.83M$2.94B$5.06B$9.08BDividend YieldN/A1.90%4.84%4.21%P/E Ratio-2.3245.94102.6717.15Price / Sales8.28411.851,121.74116.80Price / CashN/A182.1041.3037.88Price / Book0.973.894.744.78Net Income-$132.49M-$42.21M$119.11M$225.60M7 Day Performance-9.82%-2.14%-1.86%-1.21%1 Month Performance-1.50%4.21%11.37%3.09%1 Year Performance-11.24%18.39%30.22%16.48% C4 Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CCCCC4 Therapeutics2.0625 of 5 stars$3.95+2.6%$10.67+170.0%-9.2%$278.83M$33.67M-2.32150Analyst UpgradeNews CoveragePositive NewsCALTCalliditas Therapeutics AB (publ)0.0677 of 5 stars$40.00-0.4%$39.25-1.9%N/A$1.19B$1.60B-21.62180SPRYARS Pharmaceuticals2.9441 of 5 stars$12.22+2.7%$24.00+96.4%+121.8%$1.19B$30,000.00-23.3390Insider TradeNews CoverageSNDXSyndax Pharmaceuticals3.96 of 5 stars$13.84-0.6%$37.64+171.9%-33.6%$1.18B$16M-3.84110News CoverageANIPANI Pharmaceuticals4.8302 of 5 stars$55.89-1.2%$77.71+39.0%+1.9%$1.18B$555.46M-102.89642Insider TradeRCKTRocket Pharmaceuticals4.8035 of 5 stars$11.96-0.5%$51.00+326.4%-58.6%$1.09BN/A-4.37240Analyst ForecastBCYCBicycle Therapeutics3.5984 of 5 stars$15.39+11.4%$36.00+133.9%-18.8%$1.06B$26.98M-4.56240Analyst ForecastInsider TradeAnalyst RevisionNews CoverageHigh Trading VolumeAVDLAvadel Pharmaceuticals2.6696 of 5 stars$10.94+5.3%$24.43+123.3%-24.0%$1.05B$138.16M-13.15154Positive NewsCOLLCollegium Pharmaceutical3.8334 of 5 stars$30.57+1.6%$42.60+39.4%-0.4%$985.88M$599.25M12.97210News CoveragePositive NewsSEPNSepterna2.2145 of 5 stars$21.96-1.9%$43.67+98.8%N/A$975.02MN/A0.00N/ABCAXBicara TherapeuticsN/A$17.50flat$43.00+145.7%N/A$952.28MN/A0.0032Gap Down Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Competitors ARS Pharmaceuticals Competitors Syndax Pharmaceuticals Competitors ANI Pharmaceuticals Competitors Rocket Pharmaceuticals Competitors Bicycle Therapeutics Competitors Avadel Pharmaceuticals Competitors Collegium Pharmaceutical Competitors Septerna Competitors Bicara Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CCCC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CCCC Stock Alerts